Abstract
Prasugrel, a prodrug, is a novel and potent inhibitor of platelet aggregation in vivo. The metabolism of prasugrel and the elimination and pharmacokinetics of its active metabolite, 2-[1-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-mercapto-3-piperidinylidene]acetic acid (R-138727), three inactive metabolites, and radioactivity were determined in five healthy male subjects after a single 15-mg (100 μCi) p.o. dose of [14C]prasugrel. Prasugrel was rapidly absorbed, and maximum plasma concentrations of radioactivity and R-138727 were achieved in 30 min, indicating rapid formation of R-138727. Prasugrel was extensively metabolized in humans, first by hydrolysis to a thiolactone, followed by ring opening to form R-138727, which was further metabolized by S-methylation and conjugation with cysteine. Total radioactivity was higher in plasma than in blood, suggesting limited penetration of prasugrel metabolites into red blood cells. Approximately 70% of the dose was excreted in the urine and 25% in the feces.
Footnotes
-
A portion of this work was presented at the 13th North American ISSX/20th JSSX Meeting, Maui, Hawaii, 2005 and was published in an abstract form in Drug Metab Rev37 (Suppl 2):86.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.106.014522.
-
ABBREVIATIONS: prasugrel, (±)-2-[2-acetyloxy-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)ethanone; R-138727, 2-[1-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-mercapto-3-piperidinylidene]acetic acid; R-95913, 2-[2-oxo-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)ethanone; R-106583, 2-[1-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-(methylthio)-3-piperidylidene]acetic acid; R-119251, (Z)-4-[(R)-2-amino-2-carboxyethyldisulfanyl]-3-carboxymethylidene-1-(α-cyclopropylcarbonyl-2-fluorobenzyl)piperidene; R-118443, 4-[(R)-2-amino-2-carboxyethyldisulfanyl]-3-carboxymethyl-1-(α-cyclopropylcarbonyl-2-fluorobenzyl)-1,2,5,6-tetrahydropyridine; R-100932, 2-[1-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-(methylthio)-1,2,5,6-tetrahydropyridin-3-yl]acetic acid; HPLC, high-performance liquid chromatography; LC/MS/MS, liquid chromatography/tandem mass spectrometry; LSC, liquid scintillation counting; AUC, area under the plasma concentration versus time curve; MS, mass spectrometry; DTT, dithiothreitol.
- Received January 5, 2007.
- Accepted March 29, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|